

Date: January 12, 2024

To, The Department of Corporate Service, **BSE** Limited, 1st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001. **Scrip Code – 531633**

Dear Sir,

Sub: Reply to BSE for clarification sought on significant movement in Price/Volume. Ref No: L/SURV/ONL/PV/NP/ 2023-2024 / 545

This is in reference to clarification sought from Lincoln Pharmaceuticals Limited ("the Company") on January 12, 2024, in relation to significant movement in price/volume of the shares of the Company. In this regard, we would like to inform you that the Company is in compliance with SEBI (LODR) Regulations, 2015 and the Company has been promptly intimating / informing the Stock Exchange on all event(s) and information(s), which may have a bearing on the operation/performance of the Company which include all price sensitive information as and when required from time to time.

There is no undisclosed/price sensitive information or any impending announcement/corporate action which needs to be informed to the Stock Exchanges at this point of time and which may have a bearing on the price / volume behavior in the Company's scrip.

The Company has always been regular in updating the information and making the compliance with the Stock exchange. The price/volume movements in the scrip are purely on account of market sentiments and promoters/ Management of the Company are not in any manner involved in the same.

As a responsible Corporate, we would like to assure you that the Company will continue to keep the Exchanges informed at all times and adhere to compliance requirements, in the larger interest of the investors.

We trust that the above explanation clarifies the matter.

Kindly take the above information on record.

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LTD

TRUSHA SHAH COMPANY SECRETARY & COMPLIANCE OFFICER

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com





